The role of polymer conjugates in the diagnosis and treatment of cancer

S.T.P. Pharma Sciences

Volumn 6, Issue 4, 1996, Pages 237-263

  Duncan, R ^a   Dimitrijevic, S ^a   Evagorou, E G ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Drug targeting; Hydroxypropyl methacrylamide copolymers; Poly(ethylene glycol); Styrene maleic anhydride neocarzinostatin

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CAMPTOTHECIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 6; MELPHALAN; MITOMYCIN C; PACLITAXEL; PLATINUM DERIVATIVE; POLYMER; TUMOR NECROSIS FACTOR ALPHA; ZINOSTATIN;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER THERAPY; DRUG CONJUGATION; DRUG TARGETING; HUMAN; REVIEW;

EID: 0030484881     PISSN: 11571489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (181)

1. SEYMOUR L. - Synthetic polymers with intrinsic anticancer activity. - J. Bioact. Compat. Polymers, 6, 178-216, 1991.
2. RINGSDORF H. -Structure and properties of pharmacologically active polymers. - J. Polym. Sci. Polymer Symp., 51, 135-53, 1975.
3. GROS L., RINGSDORF H. and SCHUPP H. - Polymeric antitumour agents on a molecular and cellular level. - Angew. Chemie Int. Ed. Eng., 20, 301-323, 1981.
4. NUCCI M.L., SHORR and ABUCHOWSKI A. - The therapeutic values of poly(ethylene glycol)-modified proteins. - Adv. Drug Delivery Rev., 6, 133-151, 1991.
5. FRANCIS G.E., DELGADO C., FISHER D., MALIK F. and ARGRAWAL A.K. - Polyethylene glycol modification : relevance to improved methodology to tumour targeting. - J. Drug Targeting, 3, 321-340, 1996.
6. MAEDA H. - SMANCS and polymer-conjugated macromolecular drugs : advantages in cancer chemotherapy. - Adv. Drug Del. Rev., 6, 181-202, 1991.
7. KONNO T. and MAEDA H. - Targeting chemotherapy of hepatocellular carcinoma : arterial administration of SMANCS/ lipiodol. - In : Neoplasma of the Liver, K. Okada and K.G. Ishak Eds., Springer Verlag, New York, 1987, pp. 343-352.
8. KURTZBERG J., MOORE J. O., SCUDIERY D. and FRANKLIN N.J. - A Phase II study of polyethylene glycol (PEG) conjugated L-asparaginase in patients with refractory acute leukæmias. - Proc. Am. Soc. Cancer Res., 29, 213, 1988.
9. VASEY P.A., DUNCAN R., KAYE S.B. and CASSIDY J. - Clinical Phase I trial (HPMA copolymer doxorubicin). - Eur. J. Cancer, 31A, S193, 1995.
10. CHARLISH P.-Improved drug targeting : polymer therapeutics. - Pharmaprojects Magazine, January 1996, pp. 16-19.
11. DUNCAN R. and KOPECEK J. - Soluble synthetic polymers as potential drug carriers. - Adv. Polymer Sci., 57, 51-101, 1984.
12. DUNCAN R.-Drug-polymer conjugates : potential for improved chemotherapy. - Anti-Cancer Drugs, 3, 175-210, 1992.
13. DUNCAN R. and SPREAFICO F. - Polymer conjugates: pharmacokinetic considerations for design and development. - Clinical Pharmacokinetics, 27, 290-306, 1994.
14. HOES C.J.T. and FEIJEN J.- The applications of drug-polymer conjugates in chemotherapy.-In : Drug-Carrier Systems, F.H.D. Roerdink and A.M. Kroon Eds., Wiley and Sons Ltd., Chichester, 1989, pp. 57-109.
15. SEZAKI H., TAKAKURA Y. and HASHIDA M. - Soluble macromolecular carriers for delivery of antitumour agents. - Adv. Drug Del. Rev., 3, 247-66, 1989.
16. KRINICK N.L. and KOPECEK J. - Soluble polymers as targetable drug carriers. - In : Targeted Drug Delivery, Handbook of Experimental Pharmacology, R.L. Juliano Ed., Springer Verlag, Berlin, 1991, pp.105-179.
17. PUTTNAM D. and KOPECEK J. - Polymer conjugates with anticancer activity. - Adv. Polym. Sci., 122, 55-123, 1995.
18. CALIBRESI P. and CHABNER B.A. - Chemotherapy of neoplastic diseases. - In : The Pharmacological Basis of Therapeutics, J.G. Hardman and L.E. Limbird Eds., McGraw-Hill, New York, 1996, pp. 1225-1288.
19. KWON G.S. and KATAOKA K. - Block copolymer micelles as long-circulating drug vehicles. - Adv. Drug Del. Rev., 16, 295-309, 1995.
20. CASSIDY J., NEWELL D.R., WEDGE S.R. and CUMMINGS J. - Pharmacokinetics of high molecular weight agents. - Cancer Surveys, 17, 315-341, 1993.
21. CUVIER C., ROBLOT-TREUPEL L., MILLOT J.M., LIZARD G., CHEVILLARD S., MANFAIT M., COUVREUR P. and POUPON M.F. - Doxorubicin-loaded nanospheres bypass tumour cell multidrug resistance. - Biochemical Pharmacology, 44, 509-517, 1992.
22. MATSUMURA Y. and MAEDA H. - A new concept for macromolecular therapeutics in cancer chemotherapy ; mechanism of tumoritropic accumulation of proteins and the antitumour agent SMANCS. - Cancer Res., 6, 6387-6392, 1986.
23. MAEDA H. and MATSUMURA Y. - Tumoritropic and lymphotropic principles of macromolecular drugs. - CRC Crit. Rev. Ther. Drug Carrier Sys., 6, 193-210, 1989.
24. SEYMOUR L.W. - Passive tumour targeting of soluble macromolecules and drug conjugates. - CRC Crit. Rev. Ther. Drug Carrier Sys., 9, 135-187 1992.
25. MAEDA H., UEDA M., MORINAGA T. and MATSUMOTO T. - Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumour protein neocarzinostatin : pronounced improvements in pharmacological properties. - J. Med. Chem., 28, 455-461, 1985.
26. IWAI K., MAEDA H. and KONNO T. - Use of oily contrast medium for selective drug targeting to tumour : enhanced therapeutic effect and X-ray image. - Cancer Res., 44, 2114-2121, 1984.
27. CASSIDY J., DUNCAN R., MORRISON G.J., STROHALM J., PLOCOVA D., KOPECEK J. and KAYE S.B. - Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour model.-Biochem. Pharmacol., 38, 875-879, 1989.
28. SEYMOUR L.W., ULBRICH K., STYGER P.S., BRERETON M., SUBR V., STROHALM J. and DUNCAN R. -Tumouritropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. - Brit. J. Cancer, 70, 636-641, 1994.
29. SEYMOUR L.W., MIYAMOTO Y., BRERETON M., STYGER P.S., MAEDA H., ULBRICH K. and DUNCAN R. - Influence of molecular size on passive tumour-accumulation of soluble macromolecular drug carriers. - Eur. J. Cancer, 5, 766-770, 1995.
30. YUAN F., DELLIAN M., FUKUMURA D., LEUNIG M., BERK D.A., TORCHILIN V.P. and JAIN R.K. - Vascular permeability in a human tumour xenograft : molecular size dependence and cutoff size. - Cancer Res., 55, 3752-3756, 1995.
31. YUAN F., LEUNIG M., SHI KUN H., BERK D.A., PAPAHADJOPOULOS D. and JAIN R.K. - Microvascular permeability and interstitial penetration of sterically stabilised (stealth) liposomes in a human tumour xenograft. - Cancer Res., 54, 3352-2256, 1994.
32. LI C.J., MIYAMOTO Y., KOJIMA Y. and MAEDA H. - Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. - Br. J. Cancer, 67, 975-980, 1993.
33. DUNCAN R., SEYMOUR L.C.W., SCARLETT L., LLOYD, J.B., REJMANOVA P. and KOPECEK J. - N-(2-hydroxypropyl)-methacrylamide copolymers with pendant galactosamine residues. Fate after intravenous administration to rats. - Biochim. Biophys. Acta, 880, 62-71, 1986.
34. SEYMOUR L.W., FLANAGAN P.A., AL-SHAMKHANI A., SUBR V., ULBRICH K., CASSIDY J.A. and DUNCAN R. - Synthetic polymers conjugated to monoclonal antibodies : vehicles for tumour-targeted drug delivery. - Sel. Cancer Therap., 7, 59-73, 1991.
35. ULBRICH K., STROHALM J., SUBR V., PLOCOVA D., DUNCAN R. and RIHOVA B. - Polymeric conjugates of drugs and antibodies for site-specific delivery. - Makromol. Symp., 103, 177-192, 1996.
36. OMELYANENKO V., KOPECKOVA P., GENTRY C., SHIAH J-G. and KOPECEK J. - HPMA copolymer-anticancer drug OVTL16 antibody conjugates. 1. Influence of the method of synthesis on binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. - J. Drug Targeting, 3, 357-374, 1996.
37. DUNCAN R., CABLE H.C., REJMANOVA P., KOPECEK J. and LLOYD J.B.-Tyrosinamide residues enhance pinocytic capture of N-(2- hydroxypropyl)methacrylamide copolymers. - Biochim. Biophys. Acta, 799, 1-8, 1984.
38. WEDGE S.R.-Mechanism of action of polymer anthracyclines : potential to overcome multidrug resistance. - Ph. D. Thesis, Keele University, 1990.
39. YOKOYAMA M. - Block copolymers as drug carriers. - Crit. Rev. Therap. Drug Carrier Systems, 9, 213-248, 1992.
40. FLANAGAN P.A., RIHOVA B., SUBR V., KOPECEK J. and DUNCAN R. - Immunogenicity of protein-N-(2-hydroxypropyl)-methacrylamide copolymer conjugates measured in A/J and B10 mice. - J. Bioact. Compat. Polymers, 5, 151-166, 1990.
41. SEYMOUR L.W., DUNCAN R., STROHALM J. and KOPECEK J. - Effect of molecular weight (Mw) of N-(2-hydroxypropyl)-methacrylamide copolymers on body distribution and rate of excretion after subcutaneous intraperitoneal and intravenous administration to rats. - J. Biomed. Mater. Res., 21, 1341-1358, 1987.
42. GODDARD P., WILLIAMSON I., BROWN J., HUTCHINSON L.E., NICHOLLS J. and PETRAK K. - Soluble polymeric carriers for drug delivery. Part 4. Tissue autoradiography and following intravenous administration. -J. Bioact. Compat. Polymers, 6, 4-24, 1991.
43. REGLESEN W. - Anionic dyes, heparin, and heparinoids - the rediscovery of polyanionic antitumour agents. - J. Natl. Cancer Inst., 81, 1920-1930, 1989.
44. OTTERLEI M., OSTGAARD K., SKJAK-BRAEK G., SMIDSROD O., SOON-SHIONG P. and ESPEVIK T. - Induction of cytokine production from human monocytes stimulated with alginate. - J. Immunother., 10, 286-291, 1991.
45. AL-SHAMKHANI A. and DUNCAN R. - Alginates as a macromolecular drug delivery system for the antitumour agent daunomycin : synthesis, controlled release properties and antitumour activity of alginate-cis-aconityl-daunomycin conjugates. - Int. J. Pharm., 122, 107-119, 1995.
46. VERCAUTEREN R., BRUNEEL D., SCHACHT E. and DUNCAN R. - Effect of the chemical modification of dextran on the degradation by dextranases. - J. Bioactive Comp. Polymers, 5, 4-15, 1990.
47. SHALABY W.S.W. and PARK K. - Chemical modification of proteins and polysaccharides and its effect on enzyme-catalysed degradation. - In : Biomedical Polymers. Designed-to-degrade Systems, S.W. Shalaby Ed., Hanser Publishers, New York, 1994, pp. 213-258.
48. KABANOV A.V. and ALAKHOV V.Y. - New approaches to targeting bioactive compounds. -J. Cont. Rel., 28, 15-35, 1994.
49. YOKAYAMA M., OKANO T., SAKURAI Y. and KATAOKA K. - Improved synthesis of adriamycin-conjugates poly(ethylene oxide)-poly(aspartic acid) block copolymer and formation of unimodal micellar structure with controlled amount of physically entrapped adriamycin. - J. Cont. Rel., 32, 269-277, 1994.
50. KATAOKA K., KWON G.S., YOKOYAMA M., OKANO T. and SAKURAI Y. - Block copolymer micelles as vehicles for drug delivery. -J. Cont. Rel., 24, 119-132, 1993.
51. ANGELUCCI F., BERSANI L., CARUSO M., RIPAMONTI M., RUGGIERI M. and SUARATO A. - GB Patent Application 17024, 1991.
52. 1H-NMR : FCE28068 and FCE 28069. - Magnetic Resonance in Chemistry, in press, 1996.
53. MENDICHI R., RIZZO V., GIGLI M. and GIACOMETTI SCHIERONI A. - Molecular characterization of polymeric antitumour drug carriers by size exclusion chromatography and universal calibration. - J. Liquid Chromatography, in press, 1996.
54. CONFIGLIACCHI E., RAZZANO G., RIZZO V. and VIGEVANI A. - HPLC methods for the determination of bound and free doxorubicin and of bound and free galactosamine in methacrylamide polymer-drug conjugates. - J. Pharm. Biomed. Analysis, in press, 1996.
55. CAVALLO A., ADAMI M., MAGRINI R. and COLOMBO G.-PK1/PK2 lyophilised formulations, HPMA/doxorubicin conjugates with potentially improved antitumour activity. - Proc. 1st World Meeting APGI/AVP, Budapest, 1995, pp. 843-844.
56. DUNCAN R., HUME I.C., YARDLEY H.J., FLANAGAN P.A., ULBRICH K., SUBR V. and STROHALM J. - Macromolecular prodrugs for use in targeted cancer chemotherapy : melphalan covalently coupled to N-(2-hydroxypropyl)methacrylamide copolymers. -J. Cont. Rel., 16, 121-136, 1991.
57. HIRANO T., RINGSDORF H.and ZAHARKO D. - Antitumour activity of monomeric and polymeric cyclophosphamide derivative compound with in vitro hydrolysis. - Cancer Res., 40, 2263-2267, 1980.
58. GIAMMONA G., CARUSI B., CAVALLARO G., PITTARESI G. and PALAZZO S. -Anticancer agent coupled to polyaspartamide as drug carrier. - Eur. J. Pharm. Biopharm., 38, 159-162, 1992.
59. DEMARRE A. and SCHACHT E. - Preparation of 4-nitrophenyl esters of poly[N-5-(2-hydroxyethyl) - L- glutamine] and coupling with bioactive agents. - Makromol. Chem., Macromolecular Chemistry and Physics, 193, 3023-3030, 1992.
60. PRZYBYLSKI M., FELL E., RINGSDORF H. and ZAHARKO D. - Pharmacologically active polymers. 17. Synthesis and characterization of polymeric derivatives of the antitumour agent methotrexate. - Makromol. Chem., 179, 1719-1733, 1978.
61. CHU B.C.F. and HOWELL S.B. - Pharmacological and therapeutic properties of carrier bound methotrexate against tumour confined to a third space body compartment.-Pharmacol. Exp.Ther., 219, 389-393, 1981.
62. YASHIMA E., UCHIDA S., AKASHI M., MIYAUCHI N., MORITA N. and MINOTA T. - Polymer drugs and polymeric drugs. Part VII. Antitumour conjugated polymeric drugs consisting of 5-fluorouracil and polyanionic polymers. - J. Bioact. and Compat. Polymers, 5, 53-64, 1990.
63. OHYA Y., HUANG T. Z., OUCHIT., HASEGAWA K., TAMURA J., KADOWAKI K., MATSUMOTO T. and SUZUKI S. - α-1,4-polygalactosamine immobilised 5-fluorouracils through hexamethylene spacer groups via urea bonds. - J. Controlled Release, 17, 259-266, 1991.
64. OHYA Y., INOSAKA K. and OUCHI T. - Synthesis and antitumour activity of 6-O-carboxymethyl chitin fixing 5-fluorouracil through pentamethylene, monomethylene spacer groups via amide, ester bonds - Chem. Pharm., Bull., 40, 559-561, 1992.
65. PUTNAM D.A. and KOPECEK J. - Enantioselective release of 5-fluorouracil from N-(2-hydroxypropyl) methacrylamide-based copolymers via lysosomal enzymes. - Bioconjugate Chem., 6, 483-492, 1995.
66. PUTNAM D.A. - Biorecognisable polymerconjugates containing 5-fluorouracil for the treatment of colon cancer. - Ph. D. Thesis, University of Utah, 1996.
67. NICHIFOR M., COESSENS V. and SCHACHT E. - Molecular prodrugs of 5-fluorouracil.1. Synthesis and hydrolytic stability. - J. Bioact. and Compat. Polymers, 10, 199-222, 1995.
68. NICHIFOR M., SCHACHT E. and SEYMOUR L.W. - Macromolecular prodrugs of 5-fluorouracil. 2. Enzymatic degradation. - J. Cont. Rel., 39, 79-92, 1996.
69. LAUNCHBURY A.P. and HABBOUBI N. - Epirubicin and doxorubicin. A comparison of their characteristics, therapeutic activity and toxicity. - Cancer Treatment Reviews, 19, 197-228, 1993.
70. MAZUE G., WILLIAMS G.M., IATROPOULOS M.J., NEWMAN A.J., SAMMARTINI U., PULCI R., CASTELLINO S., SCAMPINI G., BRUGHERA M., IMONDI A.R. and PODESTÁ A. - Anthracyclines : review of genotoxicity and carcinogenicity studies. - Int. J. Oncol., 8, 525-536, 1996.
71. MAZUE G., IATROPOULOS M.J., IMONDI A.R., CASTELLINO S., BRUGHERA M., PODESTÁ A., DELLA TORRE P. and MONETA D. - Anthracyclines : a review of general and special toxicity studies. - Int. J. Oncol., 7, 713-726, 1995.
72. TRAIL P., WILLNER D. and HELLESTROM K.E.- Site-directed delivery of anthracyclines for the treatment of cancer. - Drug Dev. Res., 34, 196-209, 1995.
73. KOPECEK J. and BAZILOVA H. - Poly[N-(hydroxypropyl)-methacrylamide] - I. Radical polymerisation and copolymerisation. - Eur. Polymer J., 9, 7-14, 1973.
74. VASEY P., DUNCAN R., TWELVES C., KAYE S. B., STROLIN-BENEDETTI M., and CASSIDY J. -Clinical and pharmacokinetic phase I study of PK1 (HPMA)copolymer doxorubicin. - Annals of Oncology, 7, 97, 1996.
75. DUNCAN R., SEYMOUR L.W., O'HARE K.B., FLANAGAN P.A., WEDGE S.R., HUME I.C., ULBRICH K., STROHALM J., SUBR V., SPREAFICO F., GRANDI M., RIPAMONTI M., FARAO M. and SUARATO A. - Preclinical evaluation of polymer-bound doxorubicin. - J. Cont. Rel., 19, 331-346, 1992.
76. O'HARE K.B., DUNCAN R., STROHALM J., ULBRICH K. and KOPECKOVA P. - Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone : in vitro and in vivo evaluation against murine melanoma. - J. Drug Targeting, 1, 217-229, 1993.
77. DUNCAN R., HUME I.C., KOPECKOVA P., ULBRICH K., STROHALM J. and KOPECEK J. - Anticancer agents coupled to N-(2-hydroxypropyl) methacrylamide copolymers. 3. Evaluation of adriamycin conjugates against mouse leukæmia L1210 in vivo. - J. Cont. Rel., 10, 51-63, 1989.
78. DUNCAN R. - Reduction of anticancer drug toxicity. - In : Pharmacologic, Biologic, Immunologic and Gene Therapeutic Approaches, W.J. Zeller, G. Eisenbrand and K. Hellmann Eds., Contrib. Oncol., 48, 170-180, 1995.
79. YEUNG T.K., HOPEWELL J.W., REZZANI G., SIMMONDS R.H., SEYMOUR L.W., DUNCAN R., BELLINI O., GRANDI M., SPREAFICO F., STROHALM J. and ULBRICH K. - Reduced cardiotoxicity of doxorubicin administered in the form of N-(2-hydroxypropyl)methacrylamide conjugates : an experimental study in the rat. - Cancer Chemother. Pharmacol., 29, 105-111, 1991.
80. RIHOVA B., ULBRICH K., STROHALM J., VETVICKA V., BILEJ M., DUNCAN R. and KOPECEK J. - Biocompatibility of N-(2-hydroxypropyl)methacrylamide copolymers containing adriamycin. Immunogenicity, effect of hæmatopoietic stem cells in bone marrow in vivo and effect on mouse splenocytes and human peripheral blood lymphocytes in vitro. - Biomaterials, 10, 335-342, 1989.
81. BIBBY M.C., DOUBLE J.A. and DUNCAN R.- Activityof polymer-bound doxorubicin (PK1) and doxorubicin in experimental murine colon tumours.- Proc. 1 st Int. Symp. on Polymer Therapeutics, London, 1996.
82. DUNCAN R., KOPECEK J., REJMANOVA P. and LLOYD J.B. -Targeting of N-(2-hydroxypropyl)methacrylamide copolymers to liver by incorporation of galactose residues. - Biochim. Biophys. Acta, 755, 518-521, 1983.
83. SEYMOUR L.W., ULBRICH K., STROHALM J. and DUNCAN R.- Pharmacokinetics of a polymeric drug carrier targeted to the hepatocyte galactose receptor. - Brit. J. Cancer, 63, 859-866, 1991.
84. FLANAGAN P., DUNCAN R., SUBR V., ULBRICH K., KOPECKOVA P. and KOPECEK J. - Evaluation of protein-N-(2-hydroxypropyl)methacrylamide copolymer conjugates as targetable drug-carriers. 2. Body distribution of conjugates containing transferrin, anti-transferrin receptor antibody or anti-Thy 1.2 antibody and effectiveness of transferrin-containing daunomycin conjugates against mouse L1210 leukæmia in vivo. - J. Cont. Rel., 18, 25-38, 1992.
85. RIHOVA B., JEGOROV A., STROHALM J., MATHA V., ROSSMANN P., FORNUSEK L. and ULBRlCH K. - Antibody targeted cyclosporin A. - J. Cont. Rel., 19, 25-40, 1992.
86. 123I-labelled N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma. - J. Drug Targeting, 3, 385-390, 1996.
87. DANHAUSER-RIEDL S., HAUSMANN E., SCHICK H.D., BENDER R., DIETZFELBINGER H., RASTETTER J. and HANAUSKE A.R. - Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). - Investigational New Drugs, 11 (2-3), 187-195, 1993.
88. DUNCAN R., KOPECKOVA-REJMANOVA P., STROHALM J., HUME I., LLOYD J.B. and KOPECEK J. - Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 2. Evaluation of daunomycin conjugates in vivo against L1210 leukæmia. - Brit. J. Cancer, 57, 147-156, 1988.
89. ANGELUCCI F., BALLINARI D.and FARAO M. - Synthesis and biological evaluation of polymer-bound 3′-deamino-3′[2(S)-methoxy-4-morpholinyl] doxorubicin. - Proc. XIII Int. Symp. Med. Chem., Paris, 19-23 Sept., 1994.
90. MUNECHIKA K., SOGAME Y., KISHI N., KAWABATA Y., UEDA Y., YAMANOUCHI K. and YOKOYAMA K. - Tissue distribution of macromolecular conjugate adriamycin linked to oxidized dextran, in rat and mouse bearing tumour-cells. - Biol. Pharm. Bull., 17 (9), 1193-1198, 1994.
91. BERNSTEIN A., HURWITZ E. and ARNON R. - Higher antitumour efficacy of daunomycin when linked to dextran : in vivo and in vitro studies. - J. Natl. Cancer Inst., 60, 379-384, 1978.
92. SHIH LB., GOLDENBERG D.M., XUAN H., LU H., SHARKEY R.M. and HALL T.C. - Anthracycline immunoconjugates prepared by a site-specific linkage via an amino-dextran intermediate carrier. - Cancer Res., 51, 4192-4198, 1991.
93. OHYA Y., NONOMURA K. and OUCHI T. - In vivo and in vitro antitumour activity of CM-chitin immobilized doxorubicins by lysosomal digestible tetrapeptide spacer groups. - J. Bioact. Compat. Polymers, 10, 223-234, 1995.
94. NOGUSA H., YANO T., OKUNO S., HAMANA H. and INOUE K. - Synthesis of carboxymethylpullulan-peptide-doxorubicin conjugates and their properties. - Chem. Pharm. Bull., 43, 1931-1936, 1995.
95. 5-(2-hydroxyethyl)-L-glutamine]. - J. Cont. Rel., 38, 245-266, 1996.
96. HRDINA R., BOGUSOVA A., KUNOVA A. and KVETINA J. - Changes in the toxicity and therapeutic efficacy of daunorubicin linked with a biodegradable carrier. - Neoplasma, 38 (3), 265-273, 1991.
97. HOES C.J.T., GROOTOONK J., DUNCAN R., HUME I.C., BHAKOO M., BOUMA, J.M.W. and FEIJEN J. - Biological properties of adriamycin bound to biodegradable polymeric carriers. - J. Cont. Rel., 23, 37-53, 1993.
98. PRATESI G., TORTORETO M. and ZUNINO F. - Increased effect of doxorubicin linked to pyran copolymer in the intracavity treatment of human ovarian carcinoma in nude mice. - Reg. Cancer Treat., 3, 40-43, 1990.
99. GAAL D. and HUDECZ F. - Enhancement of antitumour activity of daunomycin by conjugation to a new toxicity modulator, amphoteric branched polypeptide. - Proc. 9th NCI-EORTC Symp. on New Drugs in Cancer Therapy, Amsterdam, 12-15 March, (410), 116, 1996.
100. PRATESI G., SAVI G., PEZZONI G., BELLINI O., PENCO S., TINELLI S. and ZUNINO F. - Poly-L-aspartic acid as a carrier for doxorubicin : a comparative in vivo study of free and polymer-bound drug. - Br. J. Cancer, 52, 841-848, 1985.
101. SGOURAS D.N.F. and DUNCAN R. - Evaluation of poly(glutamic acid, alanine, tyrosine) (1:1:1) as a lung-specific drug delivery system I. Biocompatibility and studies on biodistribution in the rat. - STP Pharma Sci., 4, 87-94, 1994.
102. NATHAN A., ZALIPSKY S. and KOHN J. - Strategies for covalent attachment of doxorubicin to poly(PEG-Lys), a new water soluble poly(ether urethane). - J. Bioact. Compat. Pol., 9 (3), 239-251, 1994.
103. OHYA Y., KURODA H., HIRAI K. and OUCHI T. - Poly(ethyleneglycol) end-capped with doxorubicin via ester, amide or schiff-base bond. -J. Bioact. Compat. Polymers, 10 (1), 51-66, 1995.
104. SENTER P.D., SVENSSON H.P., SCHREIBER G.J., RODRIGUEZ J.L. and VRUDHULA V.M. - Polyethylene glycol)-doxorubicin conjugates containing beta-lactamase-sensitive linkers. - Bioconj. Chem., 6 (4), 1043-1802, 1995.
105. DE MARRE A., SOYEZ H., SCACHT E., SHOAIBI M.A., SEYMOUR L.W. and RIHOVA B. - Synthesis and evaluation of macromolecular prodrugs of mitomycin C. - J. Cont. Rel., 36, 87-97, 1995.
106. TAKAKURA Y., ATSUMI R., HASHIDA M. and SEZAKI H. - Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. II. Disposition and pharmacokinetics following intravenous and intramuscular administration. - Int. J. Pharm., 37, 145-154, 1987.
107. TAKAKURAY., KITAJIMA M., MATSUMOTO S., HASHIDA M. and SEZAKI H. - Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. I. Physicochemical characteristics and in vivo and in vitro antitumour activities. - Int. J. Pharm., 37, 135-143, 1987.
108. FLANAGAN P.A., RANUCCI E., BIGNOTTI F., FERRUTI P. and DUNCAN R. - Synthesis and evaluation of poly(amido amine)-mitomycin C conjugates. - Proc. 1st Int. Symp. Polymer Therapeutics, January 10-12, London, 52, 1996.
109. ROOS C.F., MATSUMOTO S., TAKAKURA Y., HASHIDA M. and SEZAKIH. - Physicochemical and antitumour characteristics of some polyamino acid prodrugs of mitomycin C. - Int. J. Pharm., 22, 75-87, 1984.
110. MONGELLI N., PESENTI E., SUARATO A. and BIASOLI G. - Polymer-bound paclitaxel derivatives. - US Patent, 5,362,831, 1994.
111. PESENTI E., FRANZETTI C., BIASOLI G., CIOMEI M., PASTON W., MARSIGLIO A., STEGNJAICH S., MONGELLI N. and GRANDI M. - Synthesis and biological activity of water soluble polymer-bound Taxol derivatives. - Proc. Am. Assoc. Cancer Res., 1824, 1995.
112. GREENWALD R.B., GILBERT C.W., PENDRI A., CONOVER C.D., XIA J. and MARTINEZ A. - Drug delivery systems : water soluble Taxol 2′-poly(ethylene glycol) ester prodrugs, Design and in vivo effectiveness. - J. Med. Chem., 39 (2), 424-431, 1996.
113. SUARATO A. - Novel polymeric anticancer agents. - Oral presentation, 1st International Symposium on Polymer Therapeutics, January 10-12, London, 1996.
114. RIPAMONTI M., PEZZONI G., PESENTI E., PASTORI A., FARAO M., BARGIOTTI A., SUARATO A., SPREAFICO F. and GRANDI M. - In vivo antitumour activity of FCE-23762, a methoxymorpholino derivative of doxorubicin active on doxorubicin resistant tumour cells. - Brit. J. Cancer, 65, 703-707, 1992.
115. YOKOYAMA M., MIYAUCHI M., YAMADA N., OKANO T., SAKURAI Y., KATAOKA K. and INOUE S. - Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethyleneglycol)-poly(aspartic acid) block copolymer. - Cancer Res., 50, 1693-1700, 1990.
116. YOKOYAMA M., OKANO T., SAKURAI Y., EKIMOTO H., SHIBAZAKI C. and KATAOKA K. - Toxicity and antitumour activity against solid tumours of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. - Cancer Res., 51, 3229-3236, 1991.
117. SOYEZ H., SCHACHT E., DEMARRE A. and SEYMOUR L.W. - Polymeric prodrugs of mitomycin C. - Macromol. Symp., 103, 163-176, 1996.
118. DUNCAN R., SGOURAS D., TUBUKU-METZGER A., RANUCCI E., BIGNOTTI F. and FERRUTI P. - A polymer-triton X-100 conjugate capable of pH-dependent red blood cell lysis : a model system illustrating the possibility of drug delivery within acidic intracellular compartments. - J. Drug Targeting, 2, 341-347, 1994.
119. PAZDUR R., KUDELKA A.P., KAVANAGH J.J., COHEN P.R. and RABER M.R. -The taxoids : paclitaxel (Taxol) and docetaxel (Taxotere). - Cancer Treatment Rev., 19, 351-386, 1993.
120. BISSERY M.C. - Preclinical pharmacology of docetaxel. - Eur. J. Cancer, 31(A), Suppl. 4, S1-S6, 1995.
121. GORDON M. and HOLLANDER S. - Review of platinum anticancer compounds. - J. Medicine, 24, 209-265, 1993.
122. KELLAND L. R. - New platinum antitumour complexes. - Critical Reviews in Oncology/Hæmatology, 15, 191-219, 1993.
123. KLEINBERG J. (Ed.) - Inorganic Synthesis. - McGraw-Hill, New York, 1963.
124. SCHECHTER B., PAUZNER R., ARNON R. and WILCHEK - Cisplatinum(II) complexes of carboxymethyl dextran as potential antitumour agents. I. Preparation and characterization. - Cancer Biochem. Biophys., 8, 277-287, 1986.
125. SCHECHTER B., NEUMANN A., WILCHEK M. and ARNON R. - Soluble polymers as carriers of cisplatinum. - J. Cont. Rel., 10, 75-87, 1989.
126. FILIPOVÁ-VOPRÁLOVÁ M., DROBNÍK J., RÁMEK B. and KVÉTINA J. - Biodistribution of trans-1,2-diaminocyclohexane-trimetallito-platinum(II) attached to macromolecular carriers. I. Poly(hydroxyethyl-D,L-asparagine) carrier. -J. Cont. Rel., 17, 89-98, 1991.
127. NEUSE E.W., CALDWELL G. and PERLWITZ A.G. - Cis-diaminedichtoroplatinum(II) complexes reversibly bound to water-soluble polyaspartamide carriers for chemotherapeutic applications. II. Platinum coordination to ethylenediamine ligands attached to poly(ethylene oxide)-grafted carrier polymers. - J. Inorg. Organomet. Polymers, 5, 195-207, 1995.
128. NEUSE E.W. - Macromolecular metal compounds in cancer research : concepts and synthetic approaches. - Macromol. Symp., 80, 111-128, 1994.
129. MBONYANA C.W.N., NEUSE E.W. and PERLWITZ A.G. - Monoamineplatinum(II) complexes conjugated to water soluble carrier polymers for chemotherapeutic applications. - Applied Organometallic Chemistry, 7, 279-288, 1993.
130. NEUSE W., CALDWELL G. and PERLWITZ A.G. - Cis-diaminechloroplatinum (II) complexes reversibly bound to water soluble polyaspartamides for chemotherapeutic applications. Platinum coordination to ethylenediamine ligands attached to poly(ethylene oxide)-grafted carrier polymers.- J. Inorg. and Organometallic Polymers, 5, 195-207 1995.
131. HAN M.J., PARK S.J., CHO T.J., CHANG J.Y., SOHN Y.S., LEE C.O. and CHOI S.U. - Synthesis and antitumour activity of polyanion-Pt-complexes containing alicyclic amines as ligands.-J. Bioact. Compat. Polymers, 9, 142-151, 1994.
132. SOHN Y. S., BAEK H., CHO Y. H., LEE Y.-A., JUNG O.-S., LEE C. O. and KIM Y. S. - A novel polymeric platinum(II) anticancer agent K1 30606. Preclinical studies of a water soluble polyphosphazene-Pt(DACH) conjugate. - Proc. of EORTC/NCI, Amsterdam, 1996.
133. BOGDANOV A.A. Jr, MARTIN C., BOGDANOVA A.V., BRADY T.J. and WEISSLEDER R. - An adduct of cis-diammiedichloroplatinum(II) and poly(ethylene glycol)poly(L-lysine)-succinate : synthesis and cytotoxic properties. - Bioconjugate Chem., 7, 144-149, 1996.
134. FIEBIG H.H., DREES M., RUHNAU T., MISRA H.K., ANDRUUS P. and HENDRlCKS H.R. - GB-21 a novel polymer complex with antitumouractivity in human renal and mammary xenografts. - Proc. Am. Soc. Cancer Res., 37, 297, 1996.
135. WEISS R.B. and CHRISTIAN M.C. - New cisplatin analogues in development, A review. - Drugs, 46, 360-377, 1993.
136. BURNHAM N.L. - Polymers for delivering peptides and proteins. - Am. J. Hosp. Pharm., 51, 210-218, 1994.
137. KATRE N.V. - The conjugation of proteins with polyethylene glycol and other polymers. - Adv. Drug Del. Rev., 10, 91-114, 1993.
138. HARRIS J.M. (Ed.) - Poly(ethylene glycol) Chemistry. - Plenum Press, New York, 1992.
139. MAEDA H. - Polymer conjugated macromolecular drugs for tumour-specific targeting. - In : Polymer Site-Specific Pharmacotherapy, A.J. Domb Ed., John Wiley & Sons Ltd., New York, 1994, pp. 95-116.
140. DUNCAN R., FOLKMAN J. and REGELSON W. - SMANCS. - Japn. J. Cancer Res., 86, 1234-1235, 1995.
141. KATRE N.V. and KNAUF M.J. - Solubilisation of immunotoxins for pharmaceutical compositions using polymer conjugation. - US Patent, 4,917,888, 1990.
142. KEATING M.J., HOLMES R., LERNER S. and HO D.H. - L-asparaginase and PEG-asparaginase - past, present and future. - Leukemia Lymphoma, 10, 153-157, 1993.
143. WILEMAN T.E., BENNETT M. and LILLEYMANN J. - Potential use of an asparaginase-dextran conjugate in acute lymphoblastic leukæmia. - J. Pharm. Pharmacol., 35, 762-765, 1983.
144. CHUA C.C., GREENBERG M.L., VIAU A.T., NUCCI M., BRENCKMAN W.D. and HERSHFIELD M.S. - Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia inpatient with non-Hodgkin lymphoma. - Annals Int. Med., 109 (2), 114-117, 1988.
145. FUJITA T., YASUDA Y., TAKAKURA Y., HASHIDA M. and SEZAKI H. - Alteration of biopharmaceutical properties of drugs by their conjugation with water-soluble macromolecules : uricase-dextran conjugate. - J. Cont. Rel., 11, 149-156, 1990.
146. SAVOCA K.V., DAVIS F.F., VAN ES T.T., McCOY J.R. and PALCZUK N.C. - Cancer therapy with chemically modified enzymes. II. The therapeutic effectiveness of arginase and arginase modified by covalent attachment of polyethylene glycol, on the Taper liver tumour and the L5178Y murine leukæmia. - Cancer Biochem. Biophys., 7, 261-268, 1984.
147. YOSHIMOTO T., CHAO S.G., SAITO Y., IMAMURA I., WADA H. and INADA Y. - Chemical modification of tryptophanase from E. coli with polyethylene glycol to reduce its immunoreactivity towards antitryptophanase antibodies. - Enzyme, 36, 261, 1986.
148. ABUCHOWSKI A., DAVIS F.F. AND DAVIS S. - Immunosupressive properties and circulatory life of achromobacter glutaminase-asparaginase covalently attached to polyethylene glycol in man. - Cancer Treat. Rep., 65, 1077-1081, 1981.
149. WIEDER K.J., PALCZUK N.C., VAN ES T. and DAVIS F.F. - Some properties of polyethylene glycol : phenylalamine ammonia-lyase adducts. - J. Biol. Chem., 254, 12579-12587, 1979.
150. MEYERS F.J., PARADISE C., SCUDDER S.A., GOODMAN S.A. and KONRAD M. - A Phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2. - Clin. Pharmacol. Ther., 49, 307-313, 1991.
151. CEBON J., BASSER R., CLARKE K., FOX R., GREEN M., CHIPMAN M., ZALCBERG J., MARTY J., MECHACA D., SHERIDAN W. AND BEGLEY G. - Effects of the in vivo administration of pegylated recombinant human megakaryocyte growth and development factor (MGDF) in patients with advanced cancer. - Proc. 9th NCI-EORTC Symp. on New Drugs in Cancer Therapy, March 12-15, Amsterdam, p. 202, 1996.
152. TSUTSUMI Y., TETSUNARI K., TSUNODA S.-I., OKADA N., KANEDA Y., OHSUGI Y., MIYAKE M., NAKAGAWA N. and MAYUMI T. - Polyethylene glycol modification of interleukin-6 enhances its thrombopoietic activity. - J. Cont. Rel., 33, 447-451, 1995.
153. PITT C.G. and HENDREN W. - Polyoxymethylene-oxyethylene copolymers in conjugation with biomolecules. - US Patent, 5,476,653, 1995.
154. MALIK F., DELGADO C., KNÜSLI C., IRVINE A.E., FISHER D. and FRANCIS G.E. - Polyethylene glycol (PEG)-modified granulocyte-macrophage colony-stimulating factor (GM-CSF) with conserved biological activity. - Exp. Hematol., 20, 1028-1035, 1992.
155. TANAKA H., SATEKE-ISHIKAWA R., ISHIKAWA M., MATSUKI S. and ASANO K. - Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats. - Cancer Res., 51, 3710-3714, 1991.
156. WANG Q.-C., PAI LH., DEBINSKI W., FITZ GERALD D.J. and PASTAN I. - Polyethylene glycol-modified chimeric toxin composed of transforming growth factor a and Pseudomonas exotoxin. - Cancer Res., 53, 4588-4594, 1993.
157. OHYA Y., MURATA J.-I., NISHIMOTO T. and OUCHI T. - Synthesis of a MDP analogue/chitin conjugate that stimulates cultured macrophages. - J. Bioact. Compat. Polymers, 8, 351-364, 1993.
158. KOMAZAWA H., SAIKI I., IGARASHI Y., AZUMA I., KOJIMA M., ORIKASA A., ONO M. and ITOH I. - Inhibition of tumour metastasis by a synthetic polymer containing a cell-adhesive RGDS peptide. - J. Bioact. Compat. Pol., 8, 258-274, 1993.
159. KAWASAKI K., NAMIKAWA M., MIZUTA T., INOUE S., MAEDA M. and KAKIUCHI M. - Amino-acids and peptides. 26. Laminin-related peptide poly(ethylene glycol) hybrids and their inhibitory effect on experimental metastasis. - Biol. Pharm. J., 18 (12), 1714-1717, 1995.
160. NUCCI M.L., SHORR R. and ABUCHOWSKI A. -The therapeutic value of poly(ethylene glycol) modified proteins. - Adv. Drug Delivery Rev., 6, 133-151, 1991.
161. YASUDA Y., FUJITA T., TAKAKURA Y., HASHIDA M. and SEZAKI H. - Biochemical and biopharmaceutical properties of macromolecular conjugates of uricase with dextran and polyethylene glycol. - Chem. Pharm. Bull, 38 (7), 2053-2056, 1990.
162. VAAGE J. - Local and systematic effects during interleukin-2 therapy of murine mammary tumours. - Cancer Res., 47, 4269-4298, 1987.
163. ROSENBERG S.A., LOTZE M.T., MUUL L.M., CHANG A.E., AVIS F.P., LEITMAN S., LINEHAN W.M., ROBERTSON C.N., LEE R.E., RUBIN J.T., SEIPP C.A., SIMPSON C.G. and WHITE D.E. -A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. - N. Engl. J. Med., 316, 889-897, 1987.
164. KNAUF M.J., BELL D.P., HIRTZER P., LUO Z.-P., YOUNG J.D. and KATRE N.V. - Relationship effective molecular size to systematic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers - J. Biol. Chem., 263 (29), 15064-15070, 1988.
165. ZIMMERMAN R.J., AUKERMAN S.L., KATRE N.V., WINKELHAKE J.L. and YOUNG J.D.-Shedule dependency of antitumour activity and toxicity of polyethylene glycol-modified interleukin-2 in murine tumour models. - Cancer Res., 49, 6521 - 6528, 1989.
166. METCALF D. - The colony-stimulating factors : discovery, development and clinical applications. - Cancer, 65, 2185-2195, 1990.
167. DEVITA JR V.T., HELLMAN S. and ROSENBERG S.A. (Eds.) - Cancer : Principles and Practice of Oncology. - 4th Edition, J.B. Lippincott Co., Philadelphia, 1993.
168. RIHOVA B., KRINICK N.L and KOPECEK J. - Targetable photoactivatable drugs. - J. Mat. Sci.Mater. Med., 2 , 238-242, 1991.
169. KOPECEK J., RIHOVA B. and KRINICK N. - Targetable photoactivatable polymeric drugs. - J. Cont. Rel., 16, 137-44, 1991.
170. KRINICK N.L., SUN Y., JOYNER D., SPIKES J.D., STRAIGHT R.C. and KOPECEK J. - A polymeric delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. - J. Biomat. Sci., Polymer Ed., 5, 303-324, 1994.
171. GU Z.W., SPIKES J.D., KOPECKOVA P. and KOPECEK J. - Synthesis and photoproperties of a substituted phthalocyanine-N-(2-hydroxypropyl)methacrylamide copolymer conjugate. - Coll. Czech Chem. Comm., 58, 2321-2336, 1993.
172. 6 conjugates and a preliminary study of their photodynamic effect on mouse splenocytes in vitro. - Makromol. Chem., 191, 839-856, 1990.
173. 6 towards human hepatocarcinoma cell-line (PLC/PRF/5) targeted with galactosamine and to mouse splenocytes targeted with anti-Thy 1.2 antibodies. -J. Cont. Rel. 25, 71-87, 1993.
174. MUHLER A. - Assessment of myocardial perfusion using contrast-enhanced MR imaging : current status and future developments. - Magma, 3, 21-33, 1995.
175. BOGDANOV A. A., WEISSLEDER R. and BRADY T. J. - Long-circulating blood pool imaging agents. -Advanced Drug Delivery Reviews, 16, 335-348, 1995.
176. DUNCAN R., REJMANOVA P., KOPECEK J. and LLOYD J.B.-Pinocytic uptake and intracellular degradation of N-(2-hydroxypropyl)methacrylamide copolymers. A potential drug delivery system. -Biochim. Biophys. Acta, 678, 143-150, 1981.
177. PIMM M.V., PERKINS A.C., DUNCAN R. and ULBRICH K.-Targeting of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate to the hepatocyte galactose-receptor in mice : visualisation and quantification by gamma scintigraphy as a basis for clinical targeting studies. - J. Drug Targeting, 1, 125-131, 1993.
178. 123I-labelled N-(2-hydroxypropyl)methacrylamide-doxorubicin in mice bearing transplanted melanoma and mammary carcinoma.-J. Drug Targeting, 3, 385-390, 1996.
179. WENDLAND M.F., SAEED M., YU K.K., ROBERTS T.P.L., LAUERMA K., DERUGIN N., VARADARAJAN J., WATSON A.D. and HIGGINS C.B. - Inversion recovery EPI of bolus transit in rat myocardium using intravascular and extravascular gadolinium-based MR contrast media : dose effects on peak signal enhancement. - Magn. Reson. Med., 32, 319-329, 1994.
180. BOGDANOV A.A., CALLAHAN R.J., WILKINSON R.A., MARTIN C. and CAMERON J. A. - Synthetic copolymer kit for radionuclide blood-pool imaging.-J. Nucl. Med., 35, 1880-1886, 1994.
181. HARIKA L., WEISSLEDER R., POSS K., ZIMMER C., PAPISOV M. I. and BRADY T. J. - MR lymphography with a lymphotic T1 - type MR contrast agent : Gd-DPTA-PGM. - Magn. Reson. Med., 33, 88-92, 1995.